Drug Database
AV

avapritinib

✓ Approved

Genetron Health · PDGFRA · Companion diagnostic

What is avapritinib?

avapritinib is a companion diagnostic developed by Genetron Health. It is approved for therapeutic indications via others.

Drug Profile

CompanyGenetron Health
Drug ClassCompanion diagnostic
Molecular TargetPDGFRA
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Genetron Health

Mechanism of Action

Molecular Targets

avapritinib acts on 1 molecular target:

PDGFRAplatelet derived growth factor receptor alpha (PDGFR-2, CD140A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

avapritinib is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedBirth defects research2026-09-19

Accuracy of Preliminary Birth Defect Surveillance in Utah: A Validation Study Supporting Timely Family Referrals.

Boyce Aubree A, Pocius Stephanie S

Public health surveillance is critical for understanding disease burden, yet rigorous case confirmation often introduces significant latency. The Utah Birth Defect Network (UBDN) utilizes a multistage active surveillance process that, while highly accurate, is a long and labor-intensive process. This delay creates a barrier to timely family referrals for early intervention services. This study evaluates whether preliminary surveillance data is sufficiently accurate to initiate public health actions before final clinician confirmation. We conducted a retrospective analysis of 27 monitored birth defects for delivery years 2018-2025. Positive predictive values (PPVs) were calculated for cases identified during initial medical record review by nonclinical staff compared with the "gold standard" of final clinician-led confirmation. Analysis was performed using SAS version 9.4, with 95% confidence intervals calculated via the Wilson score method. Among 1245 unique potential cases, the overall mean PPV was 68% (range: 8%-95%). Accuracy was highest for musculoskeletal defects (95%) and chromosomal anomalies (92%), with gastroschisis (95%), limb deficiencies (93%), and Trisomy 21 (92%) showing high stability. Cardiovascular defects demonstrated lower categorical accuracy (78%), with complex conditions like single ventricle (8%) showing the greatest diagnostic discordance. However, we observed categorical stability, as 77% of reclassified cardiovascular cases remained within the same body system. Preliminary surveillance reviews demonstrate high diagnostic stability for the majority of monitored conditions. These findings validate the use of preliminary data to trigger early family-centered referrals, significantly reducing the latency between case confirmation and intervention without compromising the integrity of formal reporting.

PMID 42760838
Read full article →
PubMedJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2026-09-19

Cost-Effectiveness of Thyroid Nodule Molecular Testing in Manitoba.

Lee Erika E, Chakrabarti Rana R, Viallet Norbert N, Pathak Alok A et al.

To determine the cost-effectiveness of molecular testing for indeterminate (Bethesda III/IV) thyroid nodules in a real-world, single-payer healthcare system. This retrospective population-based cohort study analyzed fine-needle aspiration biopsy (FNAB) and lobectomy data for thyroid nodules in Manitoba, Canada, during 2023. Microcosting was performed to capture surgical, surveillance, molecular testing, and complication costs in 2023 Canadian dollars. Six molecular tests (Afirma, ThyroSeqV3, ThyroidPrint, ThyroSPEC, ThyGeNEXT/ThyraMIR, and mir-THYpe) were evaluated using site-specific malignancy prevalence (21%) and published test statistics. The study was performed within a publicly funded healthcare system. Participants were 18 years and above having undergone FNAB in Manitoba.Intervention or Exposures:Three scenarios were identified Current Care, Molecular Testing, and Reference Standard (diagnostic lobectomy) pathways. The total cost per year were compared among scenarios. Cost-utility analyses compared Current Care, Molecular Testing, and Reference Standard pathways. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. A $50 000/QALY willingness-to-pay (WTP) threshold was used to interpret ICERs. Among 1486 FNABs performed, 413 were indeterminate nodules, and 149 patients underwent diagnostic lobectomy. The cost of lobectomy was $7542.69 per patient. All molecular testing strategies improved net QALYs and demonstrated ICERs ranging from $9791.03 to $58 749.94 per QALY compared to Current Care. All tests apart from Afirma were cost-effective at the WTP threshold relative to Current Care. Compared to the Reference Standard, all molecular testing strategies were dominant. For the investigated Manitoba scenario, molecular testing for indeterminate thyroid nodules can be a cost-effective strategy, possibly reducing unnecessary surgeries while preserving patient outcomes. This study contributes to the body of evidence suggesting molecular testing is cost-effective and has potential to influence political decisions in health care spending.

PMID 42760643
Read full article →
PubMedMedicine2026-09-19

Prevalence and occupational risk factors of dry eye symptoms among Chinese healthcare workers: A cross-sectional study and management implications.

Zhang Yanying Y, Zhang Jiayu J, Sun Zhigang Z, Su Chang C et al.

Healthcare workers (HCWs) in China are at a high risk of self-reported dry eye symptoms due to occupational exposures, yet population-based epidemiological data on this issue among Chinese HCWs remain scarce. This multicenter cross-sectional study aimed to quantify the prevalence of frequent dry eye symptoms, their diagnostic status, and independent occupational risk factors among Chinese HCWs. From September 2024 to December 2025, 269 active HCWs from 5 tertiary hospitals in Guangdong completed anonymous questionnaires covering demographics, occupational/lifestyle factors, and ocular symptoms. Multivariate logistic regression identified independent risk factors for frequent dry eye symptoms (≥3 times/wk). The prevalence of frequent dry eye symptoms among participants (mean age = 38.5 ± 8.2 years, 59.9% female, 74.4% were physicians) was 54.3%, but only 6.3% had a formal clinical diagnosis. Daily screen time of 7 hours or more emerged as the strongest modifiable risk factor (odds ratio [OR] = 2.31, P = .005). Other independent risk factors included perceived dry work environment (OR = 1.98), frequent night work (OR = 2.15), and myopia (OR = 1.89; all P < .01). A striking gap between knowledge, belief, and behavior was observed: 92.2% recognized screen-use risks, yet only 2.6% performed regular eye exercises. Chinese HCWs face a high burden of frequent dry eye symptoms, which remain severely underdiagnosed. The identified screen-time threshold (≥7 hours/d) is lower than conventional occupational health recommendations and should be considered a modifiable target for intervention. Importantly, current occupational health checkups for HCWs lack ocular surface screening, representing a systemic gap. Given that data were collected in the post-pandemic era (2024-2025), our findings likely reflect the new normal of digitally intensive healthcare work. Workplace-oriented interventions - such as incorporating symptom screening into annual exams, electronic medical record rest reminders, and eye care training - are urgently needed to bridge the awareness-behavior gap and protect HCWs' ocular health. Our findings are based on self-reported symptoms rather than clinical diagnosis, highlighting the need for objective screening in routine occupational health checkups.

PMID 42760669
Read full article →
PubMedMedicine2026-09-19

Development and validation of a blood-based diagnostic model for pulmonary tuberculosis combining GBP5 expression and routine laboratory indicators.

Zhao Miaomiao M, Hu Qiuxiang Q, Wang Qing Q, Cha Xinlang X et al.

WHO reports that only 54% of tuberculosis (TB) patients received rapid diagnostic tests at their initial presentation. Conventional laboratory methods in TB detection have high specificity (>90%) but low sensitivity (<50%). This means a large number of tuberculosis patients are missed. A better diagnostic approach is essential to decrease the TB burden. Studies on multi-indicator blood-based models for rapid TB diagnosis remain limited. We developed a rapid, non-sputum-based model to improve the efficiency of TB diagnosis. This was a retrospective case-control study including 301 patients with active tuberculosis (ATB) and 191 patients with other pulmonary diseases (OPD) who were evaluated at the Department of Pulmonary Medicine of the Affiliated Infectious Diseases Hospital of Soochow University between May 2023 and May 2024. A composite clinical diagnosis served as the gold standard for ATB diagnosis, including either a clinical diagnosis or bacteriological confirmation. The diagnostic outcome of ATB (ATB vs OPD) was defined as the dependent variable, while guanylate-binding protein 5 (GBP5) expression levels and routine laboratory indicators (including blood cell counts and plasma protein measurements) were defined as independent variables. Univariate and multivariate logistic regression analyses were performed to identify key predictors, and an AdaBoost algorithm was used to construct a TB diagnostic model. The performance of the model was compared with traditional laboratory-based TB tests. DeLong's Test was used to evaluate the statistical difference of AUC between AdaBoost and traditional methods. Through univariate and multivariate logistic regression analyses, the GBP5 gene, white blood cell (WBC) count, platelet (PLT) count, and prothrombin time (PT) were selected to construct an ATB diagnosis model using the AdaBoost algorithm. The AdaBoost model achieved an AUC of 0.808 in the training set and 0.805 in the test set, while the AUC of smear microscopy, MTB culture, Xpert MTB/RIF, and IGRA were 0.67, 0.59, 0.63 and 0.75 respectively. Therefore, our model demonstrated better diagnostic performance than conventional methods. This study preliminarily demonstrates that our AdaBoost diagnostic model based on GBP5 gene expression and routine blood indicators could serve as a potential tool for the clinical diagnosis of ATB. However, to be applied to the clinic, large samples are needed to validate the performance of the model.

PMID 42760747
Read full article →
PubMedJournal of the European Academy of Dermatology and Venereology : JEADV2026-09-19

From diagnostic accuracy to clinical utility in molecular dermatopathology.

Yılmaz Ercan E, Özer Nezihe Koker NK, Topal Erdem E

PMID 42760889
Read full article →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-09-19

Response: Diagnostic utility of APRI, FIB-4, and FIB-5 in intrahepatic cholestasis of pregnancy.

Cicek Sevil S, Kapudere Bilge B, Kaya Parspancı Yasemin Beyza YB, Tavukcuoglu Zehra Z et al.

PMID 42760824
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about avapritinib